This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Non-cardiothoracic Surgery  • Surgical Physiology, Other  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Outcome at All Levels of Cardiac Risk

Haytham M. A. Kaafarani, MD; Prasad V. Atluri, MD; John Thornby, PhD; Kamal M. F. Itani, MD

Arch Surg. 2008;143(10):940-944.

Hypothesis  We hypothesized that the relationship among β-blocker use, heart rate control, and perioperative cardiovascular outcome would be similar in patients at all levels of cardiac risk.

Design  Retrospective cohort study.

Setting  Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.

Patients  Among all patients who underwent various noncardiac surgical procedures in 2000, those who received perioperative β-blockers were matched and compared with a control group from the same patient population.

Main Outcome Measures  Thirty-day stroke, cardiac arrest, myocardial infarction, and mortality, as well as mortality at 1 year.

Results  Patients at all levels of cardiac risk who received β-blockers had lower preoperative and intraoperative heart rates. The β-blocker group had higher rates of 30-day myocardial infarction (2.94% vs 0.74%, P =.03) and 30-day mortality (2.52% vs 0.25%, P =.007) compared with the control group. In the β-blocker group, patients who died perioperatively had significantly higher preoperative heart rate (86 vs 70 beats/min, P =.03). None of the deaths occurred among the patients at high cardiac risk.

Conclusion  Among patients at all levels of cardiac risk undergoing noncardiac surgery, administration of β-blockers should achieve adequate heart rate control and should be carefully monitored in patients who are not at high cardiac risk.

Author Affiliations: Department of Surgery, University of South Florida, Tampa (Dr Kaafarani); Department of Surgery, Veterans Affairs Boston Health Care System, West Roxbury, and Boston University and Harvard Medical School, Boston, Massachusetts (Drs Kaafarani and Itani); and Department of Anesthesia, Baylor College of Medicine (Dr Atluri), and Biostatistical Laboratory, Michael E. DeBakey Veterans Affairs Medical Center (Dr Thornby), Houston, Texas.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

β-Blockade in Noncardiac Surgery—Invited Critique
Todd E. Rasmussen
Arch Surg. 2008;143(10):944.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade
American College of Cardiology Foundation et al.
J Am Coll Cardiol 2009;0:j.jacc.2009.07.004v1-15004.
FULL TEXT  

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
American College of Cardiology Foundation et al.
J Am Coll Cardiol 2009;0:j.jacc.2009.07.010v1-15023.
FULL TEXT  

Cardiovascular Evaluation and Management of Severely Obese Patients Undergoing Surgery: A Science Advisory From the American Heart Association
Poirier et al.
Circulation 2009;120:86-95.
ABSTRACT | FULL TEXT  

Beta-Blockers: Must We Throw the Baby Out with the Bath Water?
Stone et al.
Anesth. Analg. 2009;108:1987-1990.
FULL TEXT  

More Evidence That Perioperative {beta}-Blockers in Noncardiac Surgery Can Be Harmful
Journal Watch Hospital Medicine 2008;2008:1-1.
FULL TEXT